Can You Take Rosuvastatin and Azithromycin Together?

Taking rosuvastatin and azithromycin together is generally considered safe at standard clinical doses, but the combination requires careful monitoring because azithromycin can increase rosuvastatin levels in the blood, potentially raising the risk of muscle-related side effects. While no absolute contraindication exists between these drugs, patients and prescribers should be aware of the underlying pharmacological interaction and take precautions, especially in patients with kidney disease, high doses, or additional risk factors for statin-induced muscle injury.

What the FDA Says

Neither the rosuvastatin nor azithromycin FDA labels formally list each other as a contraindicated drug combination. However, both labels contain important safety language that clinicians and patients should understand.

The rosuvastatin label (FDA Drug Labeling via OpenFDA) notes that the drug is metabolized through multiple pathways, with approximately 10% hepatic metabolism via cytochrome P450 enzymes and the majority of the drug cleared unchanged in urine and bile. The label warns that increased plasma concentrations of rosuvastatin have been observed when the drug is coadministered with certain medications that inhibit or compete for metabolism.

The azithromycin label identifies azithromycin as a moderate inhibitor of cytochrome P450 3A4 (CYP3A4) and notes that it can increase the plasma concentrations of drugs metabolized by this enzyme. While rosuvastatin is not primarily a CYP3A4 substrate (unlike simvastatin or atorvastatin), azithromycin's broad metabolic effects and ability to alter drug transporters mean that clinically relevant interactions are possible.

The severity rating for this combination is generally moderate: the interaction is unlikely to cause harm in most patients at standard doses, but requires awareness and monitoring in higher-risk populations.

How This Interaction Works

Understanding the pharmacology of rosuvastatin and azithromycin reveals why this combination warrants attention, even though it is not absolutely contraindicated.

Rosuvastatin Metabolism

Rosuvastatin is unique among statins because it undergoes minimal hepatic metabolism—only about 10% is metabolized by the liver, primarily through CYP2C9 and to a lesser extent CYP3A4. Approximately 90% of the drug is excreted unchanged in the urine and bile. This profile makes rosuvastatin less prone to drug interactions compared to statins like simvastatin (which is extensively metabolized by CYP3A4) or atorvastatin (which is metabolized by CYP3A4 and CYP2C8).

However, rosuvastatin is also a substrate for organic anion transporting polypeptides (OATPs), particularly OATP1B1 and OATP1B3. These hepatic transporters actively uptake rosuvastatin into liver cells, where it exerts its therapeutic effect. Any drug that inhibits these transporters can reduce hepatic uptake of rosuvastatin, leading to higher circulating levels.

Azithromycin's Metabolic Effects

Azithromycin is a macrolide antibiotic that inhibits multiple cytochrome P450 enzymes, most notably CYP3A4. While rosuvastatin is not a primary CYP3A4 substrate, azithromycin's effects are not limited to enzyme inhibition alone. Macrolides, including azithromycin, can also inhibit hepatic drug transporters, including OATP1B1. This transporter inhibition may reduce the hepatic uptake of rosuvastatin, increasing its systemic circulation and potentially raising the risk of adverse effects.

Additionally, azithromycin is known to prolong the QT interval on an electrocardiogram—a cardiac electrolyte disturbance that, while usually benign alone, can become more concerning when combined with other medications that affect cardiac conduction.

The Practical Result

The net effect of combining these drugs is a modest but measurable increase in rosuvastatin plasma concentration. In most patients taking standard doses (5–20 mg daily), this increase does not cause clinical problems. However, in patients with renal impairment, those on higher rosuvastatin doses, or those with additional risk factors for statin myopathy (muscle pain or damage), the combination becomes riskier.

Who Is Most at Risk

Certain patient populations are at higher risk for adverse effects from the rosuvastatin-azithromycin combination:

• Chronic kidney disease (CKD): Because rosuvastatin is renally cleared, patients with reduced kidney function accumulate the drug and its metabolites. Azithromycin use in this population can further increase rosuvastatin exposure.
• Elderly patients (≥65 years): Older adults often have reduced kidney and liver function and are more susceptible to statin-induced muscle injury.
• High-dose rosuvastatin users: Patients on 20–40 mg daily face higher absolute rosuvastatin levels; azithromycin-induced increases compound this risk.
• History of statin myopathy or muscle pain: Patients who have previously experienced muscle symptoms with statin therapy are at higher risk of recurrence.
• Concurrent use of other myopathy-risk drugs: Patients also taking fibrates (e.g., gemfibrozil), certain antiretrovirals, or other CYP3A4 inhibitors face cumulative risk.
• Hypothyroidism or polymyositis: Underlying muscle or metabolic disorders increase susceptibility to statin-induced muscle injury.

Clinical Scenario 1: Uncomplicated Outpatient Use

A 55-year-old woman with stable coronary artery disease has been taking rosuvastatin 10 mg daily for 3 years with good tolerance and no muscle symptoms. She develops acute bacterial sinusitis and is prescribed azithromycin 500 mg on day 1, then 250 mg daily for 4 days. Her kidney function is normal (eGFR 78 mL/min/1.73m²). In this scenario, the interaction risk is low. The modest increase in rosuvastatin concentration is unlikely to cause clinical problems over a 5-day course of azithromycin. The patient should take both medications as prescribed and report any unusual muscle pain or weakness, but no dose adjustment is necessary. The prescriber and pharmacist should document this coadministration for awareness, but no intervention is required.

Clinical Scenario 2: High-Risk Patient

A 72-year-old man with chronic kidney disease (eGFR 35 mL/min/1.73m²) and type 2 diabetes has been treated with rosuvastatin 20 mg daily and gemfibrozil 600 mg twice daily for hypertriglyceridemia and cardiovascular risk. He has no prior history of myopathy. He develops community-acquired pneumonia and is prescribed azithromycin 500 mg on day 1, then 250 mg daily for 4 days. In this scenario, the interaction risk is significantly elevated. This patient has multiple risk factors: advanced age, reduced kidney function (which impairs rosuvastatin clearance), high-dose rosuvastatin, concurrent fibrate use (which already increases statin myopathy risk), and now a macrolide antibiotic. The recommended approach is to consider an alternative antibiotic (such as a beta-lactam or respiratory fluoroquinolone) if clinically appropriate. If azithromycin is essential, the rosuvastatin dose should be temporarily reduced (e.g., to 5–10 mg daily), and the patient should be counseled to report muscle pain, weakness, dark urine, or other signs of myopathy. Liver function and creatine kinase (CK) should be checked before starting azithromycin and again 7–10 days after completion.

What to Do

For Patients

Do not stop taking either medication without consulting your healthcare provider. The combination is not absolutely contraindicated, but awareness and monitoring are essential.

• Inform your pharmacist and doctor that you take rosuvastatin whenever you are prescribed azithromycin or another macrolide antibiotic.
• Report muscle symptoms immediately: leg pain, weakness, dark or cola-colored urine, or unusual fatigue, especially within the first 2–4 weeks of starting azithromycin or in the days following a course of the antibiotic.
• Take both medications as prescribed unless your doctor instructs otherwise.
• Stay hydrated and avoid strenuous exercise during azithromycin therapy, as dehydration and muscle stress can increase myopathy risk.
• Ask your pharmacist whether your specific rosuvastatin dose and kidney function place you at higher risk. If you have reduced kidney function or are over 65, this is especially important.

For Healthcare Providers

• Screen for risk factors: Check baseline kidney function (eGFR), liver function, and CK in patients ≥65 years or those with CKD before coadministering azithromycin with rosuvastatin.
• Consider alternatives to azithromycin in high-risk patients (those on high-dose rosuvastatin, with CKD, or concurrent fibrate use). Beta-lactams or fluoroquinolones may be safer for respiratory or urinary infections.
• Reduce rosuvastatin dose temporarily if azithromycin is necessary in a high-risk patient (e.g., reduce from 20 mg to 5–10 mg daily during and for 3–5 days after azithromycin therapy).
• Monitor and counsel: Advise patients to report muscle symptoms and consider repeat CK measurement 7–10 days after azithromycin completion in high-risk groups.
• Document the decision: Document in the medical record why the coadministration was chosen, what monitoring plan was established, and what patient education was provided.

When to Call Your Doctor or Pharmacist

Seek immediate medical attention or call your doctor right away if you experience:

• Muscle pain, weakness, or tenderness, especially in the legs or large muscle groups.
• Dark or cola-colored urine, which may indicate muscle breakdown (rhabdomyolysis).
• Unexplained fatigue or malaise during or shortly after azithromycin treatment.
• Chest pain, palpitations, or fainting, which could signal an unrelated cardiac event but warrant immediate evaluation.
• Fever, chills, or signs of a worsening infection, indicating the antibiotic may not be working.

Call your pharmacist or doctor within 24 hours if you have questions about whether it is safe to take both medications, or if you develop mild muscle aches that do not resolve quickly.

Key Takeaways

• Rosuvastatin and azithromycin can be taken together at standard doses in most patients, but the combination warrants awareness because azithromycin can increase rosuvastatin blood levels through inhibition of drug transporters and CYP3A4.
• Patients with chronic kidney disease, advanced age, high rosuvastatin doses, or concurrent use of fibrates or other interacting drugs face higher risk and should be monitored closely or considered for alternative antibiotics.
• The most important adverse effect to watch for is statin-induced myopathy (muscle pain, weakness, or dark urine), which requires immediate medical attention.
• Always inform your pharmacist and doctor about all medications you take, and report any unusual muscle symptoms during or after azithromycin treatment.
• Temporary dose reduction of rosuvastatin during azithromycin therapy may be appropriate in high-risk patients; this decision should be made collaboratively between patient and healthcare provider.

Sources

• FDA Drug Labeling for Rosuvastatin via OpenFDA: https://open.fda.gov (search rosuvastatin)
• FDA Drug Labeling for Azithromycin via OpenFDA: https://open.fda.gov (search azithromycin)
• National Institutes of Health, National Library of Medicine, PubMed: Drug transporter interactions with macrolide antibiotics and statins. https://pubmed.ncbi.nlm.nih.gov
• UpToDate: "Statin-induced adverse effects." https://www.uptodate.com
• American Heart Association / American College of Cardiology Guidelines on cholesterol management. https://www.cardiosmart.org

Related Drug Interactions

If you are taking rosuvastatin, you may also want to review information on other common statin interactions. See our guides on rosuvastatin and amiodarone interaction and rosuvastatin and gemfibrozil interaction. For other macrolide antibiotics, check atorvastatin and azithromycin interaction.

Take Your Full Medication List to Your Pharmacist

The safest way to stay informed about drug interactions is to have a complete, updated list of all medications, supplements, and over-the-counter products. Every time you fill a prescription, bring this list to your pharmacy and ask the pharmacist to review it for interactions. If you use multiple pharmacies or doctors, this becomes even more critical. Visit checkdruginteractions.com to check all of your medications at once—our comprehensive drug interaction checker is powered by over 250,000 FDA drug labels and the latest clinical data. A few minutes of checking now can prevent serious health problems later.